Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 8/2016

01-12-2016 | Review Article

A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4

Authors: Reyaz Ur Rasool, Debasis Nayak, Souneek Chakraborty, Archana Katoch, Mir Mohd Faheem, Hina Amin, Anindya Goswami

Published in: Clinical & Experimental Metastasis | Issue 8/2016

Login to get access

Abstract

Prostate apoptotic response 4 (Par-4) is coined as a therapeutic protein since owing to its diverse physiologically relevant properties, especially in the cancer perspective. Albeit, Par-4 expression is not restricted to any specific tissue/organ, apart from cell death promotion (due to challenging threats), the other biological role of Par-4 is convincingly emerging. In the recent years, several laboratories have intended to dissect the signaling or mechanisms involved in Par-4 activation to augment apoptosis cascades but new developments in Par-4 research have widened its therapeutic potential. One of these important avenues is the prevention of metastasis by pro-apoptotic Par-4. In this review, we will focus on the therapeutic perspective of Par-4 with a special reference to its (Par-4) virgin prospect of devastating metastasis control.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed
2.
3.
El-Guendy N, Zhao Y, Gurumurthy S et al (2003) Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 23(16):5516–5525CrossRefPubMedPubMedCentral
4.
Cook J, Krishnan S, Ananth S et al (1999) Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18(5):1205–1208CrossRefPubMed
5.
Nagai MA, Gerhard R, Salaorni S et al (2010) Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer. Int J Oncol 37(1):41–49CrossRefPubMed
6.
7.
Johnstone RW, Tommerup N, Hansen C et al (1998) Mapping of the human PAWR (par-4) gene to chromosome 12q21. Genomics 53(2):241–243CrossRefPubMed
8.
Shrestha-Bhattarai T, Rangnekar VM (2010) Cancer-selective apoptotic effects of extracellular and intracellular Par-4. Oncogene 29(27):3873–3880CrossRefPubMed
9.
Sells SF, Han S-S, Muthukkumar S et al (1997) Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 17(7):3823–3832CrossRefPubMedPubMedCentral
10.
Chaudhry P, Singh M, Parent S et al (2012) Prostate apoptosis response 4 (Par-4), a novel substrate of caspase-3 during apoptosis activation. Mol Cell Biol 32(4):826–839CrossRefPubMedPubMedCentral
11.
Gurumurthy S, Goswami A, Vasudevan KM et al (2005) Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 25(3):1146–1161CrossRefPubMedPubMedCentral
12.
De Thonel A, Hazoum A, Kochin V et al (2014) Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells. Cell Death Dis 5(1):e1016CrossRefPubMedPubMedCentral
13.
14.
15.
Mattson MP (2005) NFκB in the survival and plasticity of neurons. Neurochem Res 30(6–7):883–893CrossRefPubMed
16.
Chendil D, Das A, Dey S et al (2002) Par-4, a pro-apoptotic gene, inhibits radiation-induced NFκB activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 1(2):152–160CrossRefPubMed
17.
18.
Qinan W, Ling Z, Bing C (2014) PAR-4: a possible new target for age-related disease. Expert Opin Ther Targets 18(8):917–927CrossRefPubMed
19.
Burikhanov R, Shrestha-Bhattarai T, Hebbar N et al (2014) Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4. Cell Rep 6(2):271–277CrossRefPubMedPubMedCentral
20.
21.
Rangnekar VM (1998) Apoptosis mediated by a novel leucine zipper protein Par-4. Apoptosis 3(2):61–66CrossRefPubMed
22.
Johnstone RW, See RH, Sells SF et al (1996) A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms’ tumor suppressor WT1. Mol Cell Biol 16(12):6945–6956CrossRefPubMedPubMedCentral
23.
Sheng J-F, Chen W, Yu Y et al (2010) PAR-4 and hTERT expression are negatively correlated after RNA interference targeting hTERT in laryngocarcinoma cells. Tissue Cell 42(6):365–369CrossRefPubMed
24.
Zhou L, Chen B, Hua X et al (2013) Effect of newly identified hTERT-interacting proteins on telomerase activity. Acta Biochimica et Biophysica Sinica 45(8):674–682CrossRefPubMed
25.
Treude F, Kappes F, Fahrenkamp D et al (2014) Caspase-8-mediated par-4 cleavage is required for TNF-alpha-induced apoptosis. Oncotarget 5(10):2988–2998CrossRefPubMedPubMedCentral
26.
Irby RB, Kline CLB (2013) Par-4 as a potential target for cancer therapy. Expert Opin Ther Targets 17(1):77–87CrossRefPubMed
27.
28.
29.
30.
Chen X, Sahasrabuddhe AA, Szankasi P et al (2014) Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival. Cell Death Differ 21(10):1535–1545CrossRefPubMedPubMedCentral
31.
Du WW, Li X, Li T et al (2015) The microRNA miR-17-3p inhibits mouse cardiac fibroblast senescence by targeting Par4. J Cell Sci 128(2):293–304CrossRefPubMed
32.
Yang K, Shen J, Chen S-W et al (2016) Upregulation of PAWR by small activating RNAs induces cell apoptosis in human prostate cancer cells. Oncol Rep 35(4):2487–2493PubMed
33.
El-Guendy N, Rangnekar VM (2003) Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 283(1):51–66CrossRefPubMed
34.
Rah B, Amin H, Yousuf K et al (2012) A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4. PLoS One 7(9):e44039CrossRefPubMedPubMedCentral
35.
Rah B, Rasool Ru, Nayak D et al (2015) PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells. Autophagy 11(2):314–331CrossRefPubMedPubMedCentral
36.
Moreno-Bueno G, Fernandez-Marcos PJ, Collado M et al (2007) Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 67(5):1927–1934CrossRefPubMed
37.
Qiu G, Ahmed M, Sells SF et al (1999) Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 18(3):623–631CrossRefPubMed
38.
Qiu SG, Krishnan S, El-Guendy N et al (1999) Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene 18(50):7115–7123CrossRefPubMed
39.
Nalca A, Qiu SG, El-Guendy N et al (1999) Oncogenic Ras sensitizes cells to apoptosis by Par-4. J Biol Chem 274(42):29976–29983CrossRefPubMed
40.
Pruitt K, Ülkü SA, Frantz K et al (2005) Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 280(24):23363–23370CrossRefPubMed
41.
Lee JW, Lee KF, Hsu HY et al (2007) Protein expression and intracellular localization of prostate apoptosis response-4 (Par-4) are associated with apoptosis induction in nasopharyngeal carcinoma cell lines. Cancer Lett 257(2):252–262CrossRefPubMed
42.
Goswami A, Ranganathan P, Rangnekar VM (2006) The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 66(6):2889–2892CrossRefPubMed
43.
Goswami A, Burikhanov R, de Thonel A et al (2005) Binding and phosphorylation of par-4 by Akt is essential for cancer cell survival. Mol Cell 20(1):33–44CrossRefPubMed
44.
Zhuang D, Liu Y, Mao Y et al (2012) TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells. Int J Cancer 130(2):309–318CrossRefPubMed
45.
Boehrer S, Chow KU, Beske F et al (2002) In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 62(6):1768–1775PubMed
46.
47.
48.
Lu KY, Syu GD, Chen CS (2016) Liposomes in proteome microarrays for the study of lipid protein interactions. Liposomes Anal Methodol 30(3):139CrossRef
49.
Qin TJ, Ma W, Liu SX et al (2010) Secretory expression of Par-4 SAC-HA2TAT following adeno-associated virus-mediated gene transfer induces apoptosis in HepG2 cells. Mol Med Rep 3(5):749–757PubMed
50.
51.
Amin H, Nayak D, Chakraborty S et al (2015) Par-4 dependent modulation of cellular beta-catenin by medicinal plant natural product derivative 3-azido Withaferin A. Mol Carcinog 55(5):864–881CrossRefPubMed
52.
Kline CL, Shanmugavelandy SS, Kester M et al (2009) Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther 8(19):1831–1837CrossRefPubMed
53.
Zhao Y, Burikhanov R, Qiu S et al (2007) Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res 67(19):9276–9285CrossRefPubMed
54.
Notaro A, Sabella S, Pellerito O et al (2014) Involvement of PAR-4 in cannabinoid-dependent sensitization of osteosarcoma cells to TRAIL-induced apoptosis. Int J Biol Sci 10(5):466CrossRefPubMedPubMedCentral
55.
Gurumurthy S, Rangnekar VM (2004) Par-4 inducible apoptosis in prostate cancer cells. J Cell Biochem 91(3):504–512CrossRefPubMed
56.
57.
Azmi AS, Ahmad A, Banerjee S et al (2008) Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3, 3′ diindolylmethane (DIM). Pharm Res 25(9):2117–2124CrossRefPubMedPubMedCentral
58.
Mohammad RM, Muqbil I, Lowe L et al (2015) Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol Elsevier 35:S78–S103CrossRef
59.
Jagtap JC, Dawood P, Shah RD et al (2014) Expression and regulation of prostate apoptosis response-4 (Par-4) in human glioma stem cells in drug-induced apoptosis. PLoS One 9(2):e88505CrossRefPubMedPubMedCentral
60.
Chaudhry P, Fabi F, Singh M et al (2014) Prostate apoptosis response-4 mediates TGF-β-induced epithelial-to-mesenchymal transition. Cell Death Dis 5(2):e1044CrossRefPubMedPubMedCentral
61.
Bajou K, Peng H, Laug WE et al (2008) Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 14(4):324–334CrossRefPubMedPubMedCentral
62.
Akgul C, Edwards SW (2003) Regulation of neutrophil apoptosis via death receptors. Cell Mol Life Sci CMLS 60(11):2402–2408CrossRefPubMed
63.
Tan J, You Y, Xu T et al (2014) Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3 K/Akt pathway-dependent EMT. Toxicol Lett 224(1):7–15CrossRefPubMed
64.
Burikhanov R, Sviripa VM, Hebbar N et al (2014) Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nat Chem Biol 10(11):924–926CrossRefPubMedPubMedCentral
Metadata
Title
A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4
Authors
Reyaz Ur Rasool
Debasis Nayak
Souneek Chakraborty
Archana Katoch
Mir Mohd Faheem
Hina Amin
Anindya Goswami
Publication date
01-12-2016
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 8/2016
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-016-9819-5

Other articles of this Issue 8/2016

Clinical & Experimental Metastasis 8/2016 Go to the issue

Research Paper

CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy

Research Paper

Ectopic expression of MCAM/MUC18 increases in vitro motility and invasiveness, but decreases in vivo tumorigenesis and metastasis of a mouse melanoma K1735-9 subline in a syngeneic mouse model

Research Paper

Impact of disease free status on prognosis in metastatic non-small round cell soft tissue sarcomas

Research Paper

Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells

Research Paper

Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions

Research Paper

Postoperative carcinoembryonic antigen level has a prognostic value for distant metastasis and survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery: a retrospective multi-institutional analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits